A statement from the makers of Ozempic says their weight-loss drug Wegovy will be available to patients in Canada starting Monday May 6th.

Novo Nordisk’s weekly injection is approved for weight loss among patients diagnosed with obesity but is not intended for cosmetic use.

Wegovy can also be prescribed to patients who are significantly overweight and have at least one related medical condition such as high blood pressure, Type 2 diabetes or obstructive sleep apnea.

Wegovy contains the same medication sema-glutide as the diabetes drug Ozempic but at a higher dose.